Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches

Frontiers in Cardiovascular Medicine

article

Georges Jourdi¹  Anne Godier³  Marie Lordkipanidzé¹  Guillaume Marquis-Gravel¹  Pascale Gaussem³ 

[1] Research Center, Montreal Heart Institute;Faculty of Pharmacy, Université de Montréal;Université de Paris;Department of Anesthesiology and Critical Care, AP-HP, Université de Paris, Hôpital Européen Georges Pompidou;Faculty of Medicine, Université de Montréal;Service d'Hématologie Biologique, AP-HP, Université de Paris, Hôpital Européen Georges Pompidou

关键词: platelets;    aspirin;    P2Y 12 receptor antagonists;    cardiovascular disease;    precision medicine;    bleeding;    surgery;   

DOI  :  10.3389/fcvm.2022.805525

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Antiplatelet agents, with aspirin and P2Y 12 receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significant changes have been made to antiplatelet therapeutic and prophylactic strategies. The shift from a population-based approach to patient-centered precision medicine requires greater awareness of individual risks and benefits associated with the different antiplatelet strategies, so that the right patient gets the right therapy at the right time. In this review, we present the currently available antiplatelet agents, outline different management strategies, particularly in case of bleeding or in perioperative setting, and develop the concept of high on-treatment platelet reactivity and the steps toward person-centered precision medicine aiming to optimize patient care.

【 授权许可】

CC BY